Eric Bannon, has over 35 years of experience providing clinical and regulatory support for medical device companies. His expertise focuses on implementing creative regulatory and clinical strategies from development through commercialization, with experience in multiple therapeutic areas including Endoscopy, Orthopedics, Gastroenterology, Metabolic and Neurovascular Diseases.

Eric is frequently called upon by incubators and accelerators to provide expert clinical and regulatory advice for startup medical device companies. He is the primary author of dozens of 510(k)s, Investigational Device Exemption (IDE) and PMA submissions in the US and related clinical and regulatory submissions in the EU, Australia, and Asia.

Lourdes Núñez-Müller holds an MBA from IESE Business School, an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management and a Doctorate in Pharmacy from the University of Granada, Spain where she got her B.S. and M.S. in Pharmacy. She has been a PhD-level healthcare director in Sanitas (Madrid), CH -Werfen (Lexington, MA ,USA) and Biopharmaceutical Corporate Relations Liaison at the Dana-Farber Cancer Institute at Harvard Medical School (Boston, MA USA). After 5 years in Boston, she returned to Spain as Director of Knowledge Transfer, Internationalization and Entrepreneurship at PTS Granada. EIT Health & EIC Accelerator Evaluator. She has over 20 years of experience providing support for health companies.

Todd Snowden Todd holds a BSc in Bioengineering and Pre-Medicine from The Catholic University of America (Washington, USA). Todd is a highly successful international healthcare executive with more than 30+ years’ experience in life sciences companies. He has worked in product management, global sales management and as CEO for companies in molecular diagnostics, laboratory services, and medical devices such as: W.L. Gore & Associates, Interleukin Genetics, and PathoGene. During 2010-2013, he was interim CEO at PathoGene, L.L.C, a start-up molecular diagnostics development company. Currently Todd is founder/principal of Ascent Business Advisors, a strategy consulting/interim management firm he founded in 2008 focused on clinical diagnostics, medical devices and digital health start-up companies.

Jörg Landwehr is a Managing Partner at ActeaVentures GmbH. He received his PhD for his molecular endocrinology research carried out at the University Hospital Basel. After his post-doc at F. Hoffmann-La Roche, he worked there on competitor analysis, revenue forecasting, project valuation, and market analytics. He then served as BD&L Director at PharmaMar (Madrid, Spain) before co-founding ActeaVentures in 2014.

Pepa Barragán  is a Regulatory affairs (CMC) and facility compliance (cGMPs) consultant. Former FDA regulator with 15 years of combined (government and industry) experience in multiple aspects of biotechnology products regulation, drug development and research. Direct participation in the FDA approval of 15 biotechnology products (novel and biosimilars). Lead inspector in multiple pre-license inspections in 8 countries. Multilingual and dual (US/EU) citizen.  Pepa holds a PhD in Biochemistry and Molecular Biology by Complutense University (Spain) and was a visiting research fellow at Harvard (US) and Freiburg (Germany) Universities. She completed a five-year postdoctoral fellowship at the US National Institute of Allergy and Infectious Diseases, has co-authored 20 peer-reviewed scientific publications and one biotechnology patent, and has been invited speaker at several scientific and regulatory conferences.

Gustavo Fuster holds a Degree in Pharmacy from the UCM, an MBA (Biotechnology) from Aliter and studied Law at UNED. He held the position of Business Development and Patents Manager at Genetrix Corp (gaining experience in the field of monoclonal antibodies and adult stem cell technology), was Patents Manager at a Spanish patent attorney firm and Director of the Technology Transfer Office of the Andalusian Public Healthcare System (practical experience in Spanish civil, administrative and commercial law, and in advanced therapies (stem cells and tissue engineering, nanotechnology and gene therapy)). He obtained the title of Spanish Industrial Property Attorney in 2007, the title of European Patent Attorney in 2008 and the CEIPI Diploma in Patent Litigation in Europe in 2011. Currently studying a Master’s degree in bioinformatics and a Computer Engineering Degree (UOC). He joined HOFFMANN EITLE in 2011.

Mercedes Delgado is Associate Professor of Strategy and Innovation at Copenhagen Business School and Research Scientist at the MIT Innovation Initiative. She serves as Senior Institute Associate at the Institute for Strategy and Competitiveness at Harvard Business School. Delgado’s research focuses on the relationship between the regional business environment and the performance of inventors, firms, regions, and countries. She examines the role of regional clusters—geographic concentrations of related industries, firms, and supporting institutions —in job creation, innovation, entrepreneurship, inclusivity, and resilience. Delgado has developed new methods for defining and mapping industry clusters and the supply chain economy, providing tools to help firms, practitioners, and policymakers create regional and national strategies. In recent work she explores the interaction between firm location choices through the value chain and firm performance. Delgado’s work has been published in top economic, policy, and strategy journals. She served as a lead researcher on the US Cluster Mapping Project: Mapping a Nation of Regional Clusters

Oscar Alegre is a partner at DWF-RCD. He is specialized in Innovation, Entrepreneurship, as well as Intellectual and Industrial property. He regularly advises companies in the technological and biotechnological sector from the conceptualization of the business project to its successful completion. He advises companies during negotiations with investors, the establishment of shareholders agreements and flexible compensation plans, etc. Likewise, Oscar advises public research entities in the definition of their policies on intellectual and industrial property and in the technology transfers process, including the creation of spin-offs. An expert in Life Sciences, technology transfers, public law, TMT and venture capital, Oscar counts on extensive experience advising leading technological companies, multinationals, start-ups, entrepreneurs, universities, research centers, hospitals and governments.

Martha Gray Professor of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Harvard-MIT Health Sciences and Technology (HST) and Department of Electrical Engineering and Computer Sciences, MIT Focused on developing the next generation to becomes leaders in “patient-centric” biomedical research and innovation. Founder and Director of MIT linQ and founder of the Catalyst, IMPACT and IDEA2 programs. Instead of a stack of papers or dozens of patents, her success is reflected in the hundreds of leaders who are now changing the landscape in academia, the clinic, engineering, and in business. Scientific Advisory Board Member to leading organizations like Becton Dickenson, Proctor&Gamble, Austen BioInnovation Institute, Annual Review of Biomedical Engineering, Translational Health Sciences & Technology Institute, National Space Biomedical Research Institute and more

Mari-Luz Bellido is the Head of Operations in Pharmex Advanced Laboratories, a EUGMP certified pharmaceutical and cosmetic CMO. She has +20-years of experience, becoming a qualified generalist capable of understanding and integrating the major functional areas of management, quality, production, and R&D activities, combined with solid scientific foundations. She has participated in multiples projects involving drug discovery and development, in vitro diagnosis, pharma and cosmetic manufacturing. She worked for +7 years as Managing Director of Vivacell, were she led the growth of from a start-up phase as spin-off of University of Córdoba, to become part of an American organization (Emerald Health Sciences Inc). She holds a PhD in Molecular Biology, and MBA by ESIC.

Alain Bernal + 30 years of experience as senior executive in the pharmaceutical industry. Scientist by training and MBA, started his international career as general manager in Spain, Colombia and Argentina promoted to head of Human Resources (HR) for international markets and eventually to Vice-President Communications at Sanofi Pasteur, the vaccines division of Sanofi. For more than a decade, he was a member of the Company’s Executive Committee, actively involved in the definition and implementation of the company’s strategy. Alain has a unique knowledge of the vaccines’ world: in this field, he drove businesses in developing as well as in developed markets and held leadership positions at local and at global levels. As Head of HR, he designed and implemented people development strategies making sure that the company attracted key talents and had a robust succession plan. Led organizational design and change management projects. As Head of Communications, he successfully managed worldwide crisis like the first influenza pandemics (H1N1) or global products issues. Working closely with the CEO, he was the company spokesperson for +12 years. Advisor and consultant for foundations and associations evolving in the public health sector or in the field of entrepreneurship.

Maria A. Revieriego(Executive Regulatory Consultant and Co-founder of ALLADVICE REGULATORY CONSULTANTS SL). Ex-regulator at the Medicine and Healthcare products Regulatory Agency (MHRA) in the UK as a Pharmaceutical Assessor of registration dossiers. More than 20 years’ professional experience across Europe mainly in Regulatory Affairs and Product Lifecycle Management of Human Medicinal Products in different biopharmaceutical companies and business models. She worked as Regulatory Affairs Head in TiGenix (currently Takeda) where among other projects with ATMP, she was actively involved in the successfully approval of the European Marketing Authorization of Alofisel (first authorization for an allogeneic cell therapy product in Europe). Since April 2019 she established herself as a consultant and has collaborated with Biopharmaceutical Companies and Public institutions in the field of ATMPs. Lecturer in Pharmaceutical Industry Masters.

Rubén Molina‘s is the CEO and Co-Founder of INNITIUS, a startup that originated in Granada. The company is a spinoff of the University of Granada and the Andalusian Health Service. INNITIUS specializes in developing a medical device for diagnosing various women’s health pathologies. Rubén Molina holds a Master’s degree in Structural Engineering and Building Engineering from the University of Granada, as well as a PDD from IESE. In 2017, Rubén abandoned his PhD to create INNITIUS. Since then, the company has secured +7M€ of public-private funding, including an EIC Accelerator. INNITIUS has also put together a team of over 15 professionals and has made significant progress towards regulatory approval, including 2 official clinical trials and developing INNITIUS’ product from TRL3 to TRL7+.

Gabor Bethlendy Senior Executive in health-tech, life sciences and diagnostics. Founder of two start-ups. Pioneering commercial leadership across some of the most transformative technology innovations in Life Sciences; including lab-on-a-chip, microarrays, and Next-Generation Sequencing. A Unique blend of education in Biochemistry and Social Work/Therapy. Strategic doer with the vision to see new markets and execute a financial, commercial and marketing plan to build it from the ground up. Passionate Leader and coach with the domain expertise to influence and negotiate both internal and external business and scientific leaders at the highest level.

Carlos Battyán Biochemist, with cellular & molecular biology, nano & biotechnology, genetics & genomics, digital health (mainly mobile health) background, with experience in research, clinical, coaching, mentoring & business in Healthcare. Clinical Trials, decentralized-Clinical Trials & Synthetic Trials. Agile, Design Thinking, LEAN Start-up, LEGO Serious Play, business model, strategy, scaling up business & internationalization in Healthcare. Prototyping & Living Labs.’

Carmen Martín is a Regulatory/Clinical Affairs and Quality Assurance professional with more than 25 years of experience, most of them in the Medical Device Industry (included MD, IVD and SW design and development) and Consulting Services, Medical Research Centers, Molecular and Genetic Diagnostic Tests, and the Health Care Area. Focused on clinical compliance, regulatory , quality product safety, and marketing registration in the EU and US. Expertise in ensuring that regulatory strategies, product safety and performance requirements, specific standards for product requirements (GSPR), validation processes (preclinical testing, sterilization, cleanrooms), biological and toxicological evaluation, performance and clinical evaluation (scientific, analytical and clinical), and quality management systems (QMS) are effectively executed to meet business objectives, legal requirements and protect human life and health. As a lead auditor and a technical product expert, she has performed more than 200 audits, considering internal, external, and audits to accredit third-party certification bodies in accordance with ISO 13485 (training IRCA certified), 17025, 15189, 9001, 14971, 17021 (for accreditation body), cGMPs (21CFR 820), GLPs, GCP, and GXP (MD and IVD). She has a chemistry degree.

Francisco Rico (Legal & Compliance Consultant). Francisco Graduated with a degree in Law from the University of Granada and has 20 years of professional experience as an external consultant to Technology-Based Companies. He is a specialist in the development and implementation of compliance systems for the protection of the technology companies from criminal, financial or cybersecurity threats. Co-Founder and Secretary of the Employers’ Association of Granada technology companies, in 2008 he co-created the MERCURE HUB initiative, which brings together professionals from various disciplines to offer 360º strategic consulting to technology companies.

Paola Hurtado serves as Head of Strategic Projects and Head of SW Development and Clinical/Lab Data Mgt at Universal DX, an in-vitro diagnostics company developing solutions for making cancer a curable disease, where she leads key corporate projects, connecting R&D with operational and go-to-market activities and brings 15 years’ experience in biotech app development. She serves as Chief Strategy Officer for BostonExO where she is responsible for creating and executing corporate strategic initiatives, driving organizational change and innovation. They leverage exponential technologies along with an abundance mindset to help organizations stay in business and disrupt their industry. She has broad experience mentoring and training start-ups and individuals to bring them to the next level. She holds professional certifications in innovation methodologies and she is an enthusiastic member of Purpose Alliance, Bridge for Billions and OpenExO communities. She holds a MS in Business Administration and Digital Marketing and a PhD in Biotechnology.

Jean Luc Henrioul is a Bio-engineer with 33-year international experience in start-ups and SMEs’ creation, early financial consolidation, general management, business & corporate development, marketing & sales. Expertise gained in multi-faceted business and social environments: multinational companies, start-up’s, SME’s, freelance consultancy (work and residency in BE, ES, FR, HU, CI, UK)
Sectors: Pharma biotech & diagnostics, e-Health & Bio-IT, MedTech, Plant Health, Agro-food, Cosmetics, bio-based economy, …
Start-ups’ mentorship with BIC Granada, ES; ACCTiVATe and InnoRate, EU; INRAE, FR; CNRS Innovation, FR, CEA Saclay, FR, Institut Curie, FR, …( > 40 consultancy missions so far since 2002)

Almudena Moreno experience has been developed in the field of technical management and registration and maintenance of medicines, medical devices, biocides, cosmetics and food supplements. She has worked for the last 15 years in consulting as head of the Regulatory Affairs and Medical Devices area, coordinating projects and teams, and in the development of the area.

Ezequiel Olmos is an Industrial Engineer in the Technical Department of CE Marking at Omologic. His work is focused on specialized advice to manufacturers, entrepreneurs and importers in relation to the application of the requirements of the EU directives of CE Certification for any type of product in the industrial, technological and health sector. Speaker and technical trainer in CE Marking in Omologic for entrepreneurs, Clusters, Accelerators and Business Innovation Centers

Jose Antonio González Degree in Economics and Business Administration from the University of Granada. Senior Executive Program at ESADE (Madrid) and Executive Program, Innovative Management & Corporate at Babson College (Boston, USA). He has developed a long professional career of more than 28 years in the financial system, Caja Granada, BMN, Bankia, and currently, in Caixabank in the area of territorial communication. He also has academic experience as an associate professor in the Department of Business Organization at the University of Granada and is currently a professor at ESIC Business and Marketing School (Spain) in different master programs (Executive MBA, Financial Management, …) giving training mainly in the areas of corporate finance, business strategy, and entrepreneurship, with extensive experience in academic tutoring of business plans in different postgraduate programs.

Marina Marinkovic: Data scientist with physics background and significant experience applying data analysis and statistics in the biomedical field. Experience moving technologies through the different stages of development including ideation, proof-of-concept, feasibility and clinical validation in an ISO/FDA regulated environment. R&D Experimental Design, Ideation and Development, Prototyping, Design Thinking, OKR, Strategy & Commercialization, Product Release Support, Technology Evaluation and Transfer Regulatory 510K, ISO 13485 and 21 CFR 820, IRB, Manufacturing Transfer, Design Control Core Competencies Product Development, Life Sciences, Biotech, Physiology, Statistical Analysis, Data Science, Cross-Functional Team leadership. Currently working as Sr Principal Scientific Product Manager Sr Principal Scientific Product Manager at Novartis Institutes for BioMedical Research (NIBR) ·

Carlos Gonzalez Luca de Tena: Executive with more than 25 years of experience in national and multinational companies in different functional areas. Experience in Pharmaceutical-Health, FMCG, HORECA, Consulting, Industrial, Internet-IT sectors. My professional objective is framed in General Management, Commercial Management (Marketing and Sales) or Business Unit Management. 15 years in GSK as Commercial Manager. 

Jorge Arenas-Vidal  is founder and managing partner of the BioSerentia Group, a business accelerator and venture builder in deep tech health operating since 2008. During this period, he founded, invested in and held chairman and interim CEO responsibilities for two biotech startups, advised on corporate strategy and designed deep tech entrepreneurship policies and programs for public and private clients. After working as a laboratory scientist, he began his career as an executive in Arthur Andersen’s Healthcare Practice, then worked as a Director at Vitalia Consulting, which was acquired by former IBM partners. Jorge holds a PhD in Toxicology, University of Navarra, and a Master in BioScience Enterprise from The Cambridge-MIT Institute. Distinguished in BioEntrepreneurship by the University of Cambridge.

Daniel Rico is a Tenured Research Group leader (Lecturer equivalent) at Newcastle University. He is a creative researcher with expert knowledge in molecular biology and bioinformatics. His scientific method is similar to the approach of an artist: he continuously explores new ways to recycle, combine and analyse different types of biological data in order to understand how cells and organisms work. He enjoys working as part of multidisciplinary teams, aiming for synergistic interactions that lead to ideas and discoveries that are not possible to achieve in isolation.  He is currently investigating the differences of the immune system in men and women and the genome features that promote translocations in cancer.

Santiago Lozano is a Graduate in Business Administration by Universidad de Navarra and Master in Finance. Accumulated Management Experience for more than 20 years, first at Industry, later Financial Markets and more than 15 years in Venture Capital (Startups and Tech Transfer Porjects).  Associate and Tech Transfer Venture Funds Director at Clave Capital. Evaluator and different  funding programmes and collaborator with several Academia Institutions. Currently member in 15 boards of Startups, mainly health sector. We identify projects in a very early stage (even setting up the company), support them with other partners, industrial players and coinvestors, from the very beginning, investing in these new companies, to create value since product development until market positioning.

Carlos Martín Oviedo is CFO Chief Financial Officer at the Chamber of Commerce and Industry of Granada and Associate Professor at the University of Granada. Being graduated in Economics and having a Master degree in business administration Carlos has developed an intense and long career of more than 20 years of work in the field of financial consultancy with a remarked expertise in the analysis of economic and financial viability of companies and projects, financial planning and companies valuation and rating. He is also Associate Professor (PDI) at the Faculty of Economic and Business Sciences of the University of Granada, attached to the Financial Economy and Accountancy Department and teaching the subjects of Financial planning and Company valuation. He also got the DEA certification in Advanced techniques of financial and commercial planning, management and control and develop a continuous research activity in these fields.

Borja Smith consulting director with more than 20 years of experience in the life sciences sector. He has worked mainly in consulting companies, in the pharmaceutical industry and in healthcare equipment companies.  During this period he has focused his activity on advising companies and public organizations and institutions on issues as diverse as Research, Development and Innovation policies (R&D&I policies), commercial strategy or the development and launch of new drugs. The areas of greatest expertise have been those related to R&D&I policies, development of business strategies (commercial, human resources, logistics) and the conceptualization and definition of business opportunities.